| HOME >> BIOLOGY >> TECHNOLOGY |
MISSISSAUGA, ON, Nov. 1 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that Vasogen's management will present at the following investor conferences in November:
Acumen BioFin Rodman & Renshaw 9th Annual Global Healthcare Conference,
The New York Palace Hotel
Tuesday, November 6, 2007 at 11:40 a.m. (ET)
JMP Securities Healthcare Focus Conference, Four Seasons Hotel, Boston
Tuesday, November 13, 2007 at 2:00 p.m. (ET)
Lazard Capital Markets Fourth Annual Healthcare Conference,
The New York Palace Hotel
Tuesday, November 27, 2007 at 1:00 p.m. (ET)
The presentations will be webcast live and available for replay from Vasogen's website, http://www.vasogen.com.
About Vasogen:
Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.
Certain statements contained in this press release, the upcoming
presentations and webcasts, or elsewhere in our public documents constitute
"forward-looking
'/>"/>
| SOURCE Vasogen Inc. Copyright©2007 PR Newswire. All rights reserved |